These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 38869181

  • 1. Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.
    Sulsenti R, Scialpi GB, Frossi B, Botti L, Ferri R, Tripodi I, Piva A, Sangaletti S, Pernici D, Cancila V, Romeo F, Chiodoni C, Lecis D, Bianchi F, Fischetti I, Enriquez C, Crivelli F, Bregni M, Renne G, Pece S, Tripodo C, Pucillo CE, Colombo MP, Jachetti E.
    Cancer Immunol Res; 2024 Sep 03; 12(9):1147-1169. PubMed ID: 38869181
    [Abstract] [Full Text] [Related]

  • 2. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R, Frossi B, Bongiovanni L, Cancila V, Ostano P, Fischetti I, Enriquez C, Guana F, Chiorino G, Tripodo C, Pucillo CE, Colombo MP, Jachetti E.
    Front Immunol; 2021 Sep 03; 12():622001. PubMed ID: 33737929
    [Abstract] [Full Text] [Related]

  • 3. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
    Mauri G, Jachetti E, Comuzzi B, Dugo M, Arioli I, Miotti S, Sangaletti S, Di Carlo E, Tripodo C, Colombo MP.
    Oncotarget; 2016 Jan 26; 7(4):3905-20. PubMed ID: 26700622
    [Abstract] [Full Text] [Related]

  • 4. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J, Gan Y, Feng T, Li Y, Xie N, Ho CH, Lee AR, Chen X, Nappi L, Han B, Fazli L, Huang J, Gleave ME, Dong X.
    J Clin Invest; 2020 Oct 01; 130(10):5338-5348. PubMed ID: 32634132
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
    Lee AR, Gan Y, Xie N, Ramnarine VR, Lovnicki JM, Dong X.
    Cancer Sci; 2019 Jan 01; 110(1):245-255. PubMed ID: 30417466
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.
    Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP.
    Cancer Res; 2011 Sep 15; 71(18):5987-97. PubMed ID: 21896641
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
    Liu Q, Pang J, Wang LA, Huang Z, Xu J, Yang X, Xie Q, Huang Y, Tang T, Tong D, Liu G, Wang L, Zhang D, Ma Q, Xiao H, Lan W, Qin J, Jiang J.
    J Pathol; 2021 Jan 15; 253(1):106-118. PubMed ID: 33009820
    [Abstract] [Full Text] [Related]

  • 12. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
    Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T.
    Sci Rep; 2021 Jun 25; 11(1):13305. PubMed ID: 34172788
    [Abstract] [Full Text] [Related]

  • 13. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X.
    Eur Urol; 2019 Aug 25; 76(2):157-166. PubMed ID: 30910347
    [Abstract] [Full Text] [Related]

  • 14. Models of neuroendocrine prostate cancer.
    Berman-Booty LD, Knudsen KE.
    Endocr Relat Cancer; 2015 Feb 25; 22(1):R33-49. PubMed ID: 25349195
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS.
    Nat Commun; 2021 Dec 21; 12(1):7349. PubMed ID: 34934057
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
    Lee AR, Li Y, Xie N, Gleave ME, Cox ME, Collins CC, Dong X.
    Oncotarget; 2017 Apr 25; 8(17):27966-27975. PubMed ID: 28427194
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
    Okasho K, Mizuno K, Fukui T, Lin YY, Kamiyama Y, Sunada T, Li X, Kimura H, Sumiyoshi T, Goto T, Kobayashi T, Lin D, Wang Y, Collins CC, Inoue T, Ogawa O, Akamatsu S.
    Cancer Sci; 2021 Jul 25; 112(7):2781-2791. PubMed ID: 33960594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.